BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 29559732)

  • 21. Mucosal malignant melanoma - a clinical, oncological, pathological and genetic survey.
    Mikkelsen LH; Larsen AC; von Buchwald C; Drzewiecki KT; Prause JU; Heegaard S
    APMIS; 2016 Jun; 124(6):475-86. PubMed ID: 27004972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurofibromin protein loss in desmoplastic melanoma subtypes: implicating NF1 allelic loss as a distinct genetic driver?
    Kadokura A; Frydenlund N; Leone DA; Yang S; Hoang MP; Deng A; Hernandez-Perez M; Biswas A; Singh R; Yaar R; Mahalingam M
    Hum Pathol; 2016 Jul; 53():82-90. PubMed ID: 26980030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of SDHD promoter mutations in various types of melanoma.
    Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
    Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract.
    Cai YJ; Ke LF; Zhang WW; Lu JP; Chen YP
    BMC Cancer; 2021 Jun; 21(1):677. PubMed ID: 34102999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.
    Kaji T; Yamasaki O; Takata M; Otsuka M; Hamada T; Morizane S; Asagoe K; Yanai H; Hirai Y; Umemura H; Iwatsuki K
    J Dermatol Sci; 2017 Jan; 85(1):51-57. PubMed ID: 27771229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF and NRAS prognostic values in conjunctival melanoma: analysis and literature review.
    Valentín-Bravo FJ; Pérez-Rodríguez Á; García-Álvarez C; García-Lagarto E; Saornil-Álvarez MA
    Arq Bras Oftalmol; 2023; 86(5):e20230071. PubMed ID: 35544941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.
    Griewank KG; Murali R; Schilling B; Scholz S; Sucker A; Song M; Süsskind D; Grabellus F; Zimmer L; Hillen U; Steuhl KP; Schadendorf D; Westekemper H; Zeschnigk M
    Br J Cancer; 2013 Jul; 109(2):497-501. PubMed ID: 23799844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
    Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA
    Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
    Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
    J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
    [No Abstract]   [Full Text] [Related]  

  • 32. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.
    van de Nes J; Gessi M; Sucker A; Möller I; Stiller M; Horn S; Scholz SL; Pischler C; Stadtler N; Schilling B; Zimmer L; Hillen U; Scolyer RA; Buckland ME; Lauriola L; Pietsch T; Waha A; Schadendorf D; Murali R; Griewank KG
    J Neurooncol; 2016 May; 127(3):435-44. PubMed ID: 26744134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
    Zimmer L; Barlesi F; Martinez-Garcia M; Dieras V; Schellens JH; Spano JP; Middleton MR; Calvo E; Paz-Ares L; Larkin J; Pacey S; Venturi M; Kraeber-Bodéré F; Tessier JJ; Eberhardt WE; Paques M; Guarin E; Meresse V; Soria JC
    Clin Cancer Res; 2014 Aug; 20(16):4251-61. PubMed ID: 24947927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes.
    Lake SL; Jmor F; Dopierala J; Taktak AF; Coupland SE; Damato BE
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5598-604. PubMed ID: 21693616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
    Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
    Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Roles of
    Wróblewska JP; Dias-Santagata D; Ustaszewski A; Wu CL; Fujimoto M; Selim MA; Biernat W; Ryś J; Marszalek A; Hoang MP
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
    Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conjunctival Melanoma: Current Treatments and Future Options.
    Grimes JM; Shah NV; Samie FH; Carvajal RD; Marr BP
    Am J Clin Dermatol; 2020 Jun; 21(3):371-381. PubMed ID: 31965542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of recurrent mutational events in anorectal melanoma.
    Yang HM; Hsiao SJ; Schaeffer DF; Lai C; Remotti HE; Horst D; Mansukhani MM; Horst BA
    Mod Pathol; 2017 Feb; 30(2):286-296. PubMed ID: 27739435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.